Abacus Life (ABL) AI Stock Analysis

• Market Cap: $607.68M
• Dividend Yield: N/A
• Average Volume (3M): 657.17K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.68
• Revenue Growth: 69.59%
• EPS Growth: 38.07%
• Country: US
• Employees: 157
• Sector: Financial
• Sector Strength: 71
• Industry: Insurance - Life
• EPS (TTM): 0.22
• Shares Outstanding: 96,764,626
• 10 Day Avg. Volume: 765,152
• 30 Day Avg. Volume: 657,167
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.30
• Enterprise Value/Revenue: 5.89
• Enterprise Value/Gross Profit: 6.67
• Enterprise Value/Ebitda: 34.81
• 1Y Price Target: $11.80
• Price Target Upside: 87.90% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 58 Neutral
• Price Target: $6.00 ▼(-4.46% Downside)

Abacus Life's overall score is driven by strong earnings call performance and strategic corporate events. However, financial performance and valuation concerns, particularly negative profitability metrics, weigh down the score. Technical indicators suggest moderate momentum but face resistance.

Positive Factors

Earnings and Financial Performance

Abacus Life, Inc. reported results that beat expectations on revenue, adjusted EBITDA, and non-GAAP EPS, driven by strong contributions from its core life insurance settlements unit and new Asset Management unit.

Market Confidence

Management raised the guidance for adjusted net income, indicating confidence in the company's growth prospects.

Market Position

Abacus Life, Inc. is the second-largest and only publicly traded company focused on life insurance settlements, operating in a large and growing market with low penetration.

Negative Factors

Short Report Impact

Morpheus Research claimed that ABL used unreliable estimates of life expectancy provided by non-independent Lapetus Solutions to over-value ABL's portfolio of life insurance settlements.

Stock Price Decline

Shares of Abacus Life, Inc. are down 28% since a short report was released, presenting an overhang on the stock.

Abacus Life Business Overview & Revenue Model

Company Description

Abacus Life, Inc. operates as an alternative asset manager specializing in life insurance products. It purchases life insurance policies from consumers seeking liquidity and manages policies over time via trading, holding, and/or servicing. The company was founded in 2004 and is based in Orlando, Florida.

How the Company Makes Money

Abacus Life makes money primarily through the acquisition and management of life insurance policies. The company purchases these policies at a discount from their face value and continues to pay the premiums. Upon the maturity of these policies, Abacus Life collects the death benefits, with the difference between the purchase price, premiums paid, and the death benefit amounting to profit. Key revenue streams include the proceeds from policy maturities and the management of a diversified portfolio of life insurance assets. Strategic partnerships with financial advisors, brokers, and insurance companies also play a significant role in sourcing policies and expanding the company's market reach.

Abacus Life Financial Statement Overview

Summary

Abacus Life shows strong revenue growth but faces challenges with profitability and cash flow. The balance sheet is stable with manageable debt levels, but negative net income impacts return on equity.

Income Statement

Abacus Life shows a mixed income statement performance. The TTM data indicates a significant increase in total revenue compared to the previous annual period, resulting in a strong revenue growth rate. However, net profit margin is negative due to significant net losses, which raises concerns about profitability. The gross profit margin remains healthy, but the EBIT and EBITDA margins are inconsistent, reflecting volatility in operating performance.

Balance Sheet

The balance sheet of Abacus Life demonstrates a stable equity base with a reasonable equity ratio. The company has managed to maintain a low debt-to-equity ratio, indicating controlled leverage. However, the return on equity is impacted by negative net income, which is a concern for investors looking for profitable returns.

Cash Flow

The cash flow analysis is concerning as Abacus Life reports negative operating cash flow in both TTM and previous annual periods, leading to negative free cash flow. This indicates cash management challenges. The operating cash flow to net income ratio is unfavorable due to persistent net losses, which raises sustainability risks.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	134.58M	111.92M	66.40M	44.71M	22.59M	1.22M
Gross Profit	118.82M	100.55M	59.91M	38.83M	8.39M	710.01K
EBITDA	22.78M	12.72M	23.33M	34.81M	349.41K	-476.74K
Net Income	-17.97M	-23.96M	9.52M	31.68M	997.41K	1.44M
Balance Sheet
Total Assets	856.51M	874.16M	331.83M	59.09M	5.29M	3.74M
Cash, Cash Equivalents and Short-Term Investments	43.76M	131.94M	27.84M	30.05M	2.60M	1.85M
Total Debt	123.07M	385.91M	141.74M	28.33M	367.51K	65.61K
Total Liabilities	420.93M	450.87M	167.76M	30.95M	2.57M	160.70K
Stockholders Equity	435.68M	424.15M	163.93M	27.25M	915.05K	2.08M
Cash Flow
Free Cash Flow	-273.44M	-209.62M	-64.71M	10.61M	1.12M	904.09K
Operating Cash Flow	-115.89M	-208.81M	-64.52M	10.69M	1.34M	904.09K
Investing Cash Flow	-8.69M	-4.96M	2.24M	-3.70M	-241.53K	-345.00M
Financing Cash Flow	259.73M	320.12M	57.82M	22.96M	-354.58K	-329.10K

Abacus Life Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 6.28
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABL, the sentiment is Neutral. The current price of 6.28 is above the 20-day moving average (MA) of 5.55, above the 50-day MA of 5.51, and below the 200-day MA of 7.31, indicating a neutral trend. The MACD of 0.17 indicates Negative momentum. The RSI at 66.22 is Neutral, neither overbought nor oversold. The STOCH value of 91.47 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ABL.

Abacus Life Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CNO	73 Outperform	$3.69B	14.04	11.35%	1.71%	0.82%	-29.29%
Sector *	68 Neutral	$17.53B	11.67	10.43%	3.82%	9.93%	1.66%
GNW	67 Neutral	$3.46B	19.39	2.42%	―	2.61%	465.03%
CIA	65 Neutral	$255.25M	22.90	5.35%	―	-0.04%	-49.18%
BHF	59 Neutral	$2.67B	5.05	13.53%	―	59.27%	―
ABL	58 Neutral	$607.68M	―	-0.34%	―	69.59%	38.07%
AAME	57 Neutral	$58.74M	29.03	2.45%	0.69%	6.98%	―

Abacus Life Corporate Events

Abacus Life Completes Warrant Exchange Offer Successfully

On July 30, 2025, Abacus Global Management announced the successful completion of its exchange offer and consent solicitation for its public and private placement warrants. The company issued 4,183,160 shares of common stock in exchange for the tendered warrants, leading to an increase in outstanding shares to approximately 102,555,154. As a result, all warrants will be delisted from the Nasdaq by August 14, 2025, while the common stock will continue trading under the symbol ‘ABL.’ This move marks a strategic step in optimizing the company’s capital structure and market positioning.

The most recent analyst rating on (ABL) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Abacus Life stock, see the ABL Stock Forecast page.

Abacus Life Completes Successful Warrant Exchange Offer

On June 30, 2025, Abacus Global Management announced the commencement of an exchange offer and consent solicitation for its public and private placement warrants to purchase shares of common stock. The offer expired on July 29, 2025, with approximately 88% of the outstanding warrants tendered. The company received significant approval to amend the warrant agreement, allowing it to exchange each outstanding warrant for 0.207 shares of common stock. This move is expected to streamline the company’s capital structure and enhance its market positioning.

The most recent analyst rating on (ABL) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Abacus Life stock, see the ABL Stock Forecast page.

Abacus Life Launches Warrant Exchange Offer

On June 30, 2025, Abacus Global Management announced the commencement of an exchange offer and consent solicitation related to its outstanding public and private placement warrants. The company aims to simplify its capital structure and reduce the potential dilutive impact of the warrants by offering 0.23 shares of common stock in exchange for each warrant tendered. If successful, this move could increase the company’s flexibility for future financing and potentially result in an increase of approximately 5% in the total outstanding shares of common stock. The offer and consent solicitation are set to expire on July 29, 2025, and require the consent of at least 50% of the public warrant holders to amend the warrant agreement.

The most recent analyst rating on (ABL) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Abacus Life stock, see the ABL Stock Forecast page.

Abacus Life Announces Warrant Exchange Offer Plan

On June 27, 2025, Abacus Global Management, Inc. announced its plan to conduct a registered exchange offer and consent solicitation for its outstanding public and private placement warrants. The company intends to offer holders 0.23 shares of common stock for each warrant exchanged, while also seeking consent to amend the Warrant Agreement to allow a mandatory exchange at a slightly lower ratio. This move aims to streamline the company’s capital structure and potentially enhance shareholder value.

The most recent analyst rating on (ABL) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Abacus Life stock, see the ABL Stock Forecast page.

Abacus Life Holds 2025 Annual Stockholders Meeting

On June 12, 2025, Abacus Global Management, Inc. held its 2025 Annual Meeting of Stockholders where key decisions were made regarding the company’s governance and financial oversight. The meeting resulted in the re-election of Cornelis Michiel van Katwijk, Mary Beth Schulte, and Karla Radka as Class II directors for a three-year term, and the ratification of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (ABL) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Abacus Life stock, see the ABL Stock Forecast page.

Abacus Life Announces Executive Compensation Changes

On May 8, 2025, Abacus Global Management, Inc. announced salary adjustments and compensation changes for its executive team, including the CEO, CFO, and Presidents. The changes involve increased annual salaries, performance-based restricted stock units (RSUs), and annual cash bonuses tied to the company’s 2025 performance targets. The RSUs will vest based on the company’s adjusted net income performance, with a stretch target set at $140 million. Additionally, the CEO is eligible for a one-time equity bonus if certain market capitalization targets are achieved.

The most recent analyst rating on (ABL) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Abacus Life stock, see the ABL Stock Forecast page.